ALK and neoplasm: A phase III trial, KEYNOTE-024, compared pembrolizumab (PD-1 inhibitor) with platinum-doublet chemotherapy in EGFR/ALK-negative, advanced NSCLC patients with tumor positive for PD-L1 ≥ 50% [19].